49.00 -0.75 (-1.51%)
Pre-Market: 8:26AM EDT
|Bid||42.50 x 1000|
|Ask||74.24 x 900|
|Day's Range||48.66 - 50.00|
|52 Week Range||26.54 - 53.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.24|
NEW YORK, June 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Synaptics ...
A rapidly changing healthcare environment in the United States, unfavorable price movements, declining dental revenues and integration risks pose significant challenges for Patterson Companies (PDCO).
Wright Medical's (WMGI) AUGMENT Injectable Bone Graft platform has same clinical indications as the company's flagship AUGMENT Bone Graft.
The whole of fiscal 2018 demonstrates an upbeat momentum for PetMed's (PETS) new order sales, primarily backed by aggressive advertising.
Medtronic's (MDT) ActivaProgramming Application is designed for use with Samsung Galaxy Tab S2 tablets. The therapy incorporates the inputs of more than a 100 clinicians worldwide.
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
It is pretty difficult for investors to choose from MedTech bigwigs Abiomed (ABMD) and Varian Medical (VAR) as both the companies are riding on solid estimate revision and other developments.
Varian (VAR) will demonstrate four brachytherapy solutions in the American Brachytherapy Society Annual Meeting in San Francisco.
Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).
NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Genomic Health saw a major boost in trading price on Monday, with shares hitting a new high after encouraging results were published in The New England Journal of Medicine regarding data from the Trial Assigning Individualized Options for Treatment (TAILORx). The trial had found that about 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely pass on doing chemotherapy. Shares of Immunomedics also saw gains after announcing that it has entered into a clinical collaboration with Clovis Oncology.
One of the tragic features of cancer is that to treat the disease, doctors sometimes have to make the body sicker through chemotherapy. These drugs kill fast-growing cells in the body, like cancer. Unfortunately, a lot of the body’s healthy cells—like those along the digestive tract, hair follicles, and bone marrow—grow quickly, too, and become…
With Morgan Stanley calling clinical laboratory services market a safe haven, let's find out what's working in favor and against this burgeoning niche market.
Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after their tumors have been removed, U.S. researchers said on Sunday. "This is a major finding," said Dr. Larry Norton, a breast cancer expert at Memorial Sloan Kettering Cancer Center in New York, who helped organize the government-funded study more than a decade ago. "It means that maybe 100,000 women in the United States alone do not require chemotherapy," Norton said.
REDWOOD CITY, Calif., June 3, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score® results of 11 to 25. The long-awaited results of the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), provided definitive evidence that the Oncotype DX Breast Recurrence Score test identified 70 percent of early-stage breast cancer patients who receive no benefit from chemotherapy, and can be effectively treated with endocrine therapy alone.
PRA Health's (PRAH) shares gain from better-than-expected Q1 earnings. However, increasing labor-related costs in the Clinical Research wing is a headwind.